On October 26, 2019 Adagene, Inc., a clinical stage biotech company with innovative antibody discovery and engineering technologies, reported that it is presenting its lead program at international conferences (Press release, Adagene, OCT 26, 2019, View Source [SID1234548675]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the Festival of Biologics conference in Basel, Switzerland, Adagene gave a presentation on "Targeting the conserved epitopes of check points for rational single and combination immunotherapy", highlighting the unique power of Adagene’s proprietary antibody discovery technology, Dynamic Precision Library (DPL), in generating species cross-reactive antibodies to enable translational studies in immune intact animal models. The DPL system combines extensive computational design, machine learning and high throughput phage and yeast screening to generate cross-reactive antibodies targeting evolutionarily conserved epitopes with novel mechanism of actions and excellent developability.

A case study of ADG106, a species cross reactive agonist antibody which targets the conserved epitope of CD137 across human, monkey and mouse. ADG106 activates CD137 in a native ligand-like fashion, while it also blocks the reverse signaling mediated by CD137 ligand. Furthermore, ADG106 is shown to exhibit Fc-mediated strong crosslinking. ADG106 has been extensively tested for efficacy in both single and combination therapy using syngeneic mouse tumor models that are believed to be relevant preclinical models of intact immune system and highly translatable into a rational approach toward single and combination immunotherapies.

The clinical data from the ongoing phase 1, first-in-human, dose-escalation study of ADG106, will be presented in a poster session at the 2019 AACR (Free AACR Whitepaper)-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston, Massachusetts. The Phase 1 study in the United States, First-In-Human study of ADG106 in subjects with advanced or metastatic solid tumors and/or relapsed/refractory non-Hodgkin lymphoma (NCT02407990) is being conducted at NEXT Oncology (San Antonio, Texas), and consists of dose-escalation and dose-expansion phases in disease-specific cohorts.

Eli Lilly has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission .

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On October 25, 2019 SRI researchers reported it will present data from multiple programs exploring novel approaches to cancer drug targeting and delivery (Press release, SRI International, OCT 25, 2019, View Source [SID1234548674]). This includes a novel technology that leverages the immune system in a new way – by tricking it into thinking cancer cells are infected with a serious virus.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Abstract C018. Primary tumor data analysis reveals novel synthetic lethal dependencies between KRAS mutation and the spliceosome
Date/Time: Tuesday, October 29, 12:30 p.m. ET
Hall D, Hynes Convention Center

Abstract 467. Cancer-Specific Intracellular Delivery of Therapeutic Antibodies Against RAS
Date/Time: Tuesday, October 29, 12:30 p.m. ET
Hall D, Hynes Convention Center

Abstract 463. A Novel Cell-Mediated Immunotherapy for Treatment of Lung and Breast Cancer
Date/Time: Monday, October 28, 12:30 p.m. ET
Hall D, Hynes Convention Center

On October 25, 2019 Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of various cancers including prostate, colorectal and leukemia, reported that it has entered into definitive agreements with institutional investors for the sale of 2,756,340 shares of common stock (or common stock equivalents), series G warrants to purchase up to 2,756,340 shares of common stock, and series H warrants to purchase up to 2,756,340 shares of common stock in a private placement at a price of $1.814 per share and associated warrants for gross proceeds of approximately $5.0 million (Press release, Trovagene, OCT 25, 2019, View Source [SID1234542539]). The transaction is anticipated to close on or about October 29, 2019, subject to customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright & Co. is acting as exclusive placement agent for the offering.

The series G warrants are exercisable immediately with a term of five and one-half years and an exercise price of $1.56 per share. The series H warrants are exercisable immediately with a term of 18 months and an exercise price of $1.56 per share.

Trovagene intends to use the net proceeds of the private placement to fund clinical development activities and for working capital and general corporate purposes. The Company has agreed to file a resale registration statement for the shares of common stock and the shares of common stock underlying the warrants issued in the offering within 10 days pursuant to a registration rights agreement.

The securities sold in the private placement have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (SEC) or an applicable exemption from such registration requirements.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

Further information regarding the private placement can be found in the Current Report on Form 8-K that will be filed by the Company with the SEC.

On October 25, 2019 SFA Therapeutics, Inc. reported that Dr. Ira Spector, company CEO, will report on updates in the company’s clinical development plans for several new therapeutic agents they have derived from the human microbiome (Press release, SFA Therapeutics, OCT 25, 2019, View Source [SID1234542538]). The presentation will be delivered as part of the Microbiome R&D and Business Collaboration Forum on October 29th at 5:45PM at the Paradise Point Resort & Spa in San Diego, CA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!